Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen EPOGEN (epoetin alfa by Year

Name: Amgen EPOGEN (epoetin alfa by Year (AMGN)
Creator: Amgen

EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)

Quarterly Annual

Amgen EPOGEN (epoetin alfa: $0M in FY2019. No newer figure appears in the documents we track.

Latest, FY2019

Period ended Dec 31, 2019

Change on a year earlier

–

0 in FY2018

History

4 years

Since FY2016

Sources

Documents cited below

Where the FY2019 figure comes from

Source: Form 10-K (filed 2020-02-12) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Year on year	Source
FY2019	Dec 31, 2019	–	Form 10-K (filed 2020-02-12) ↗
FY2018	Dec 31, 2018	–	Form 10-K (filed 2019-02-13) ↗
FY2017	Dec 31, 2017	–	Form 10-K (filed 2019-02-13) ↗
FY2016	Dec 31, 2016	–	Form 10-K (filed 2019-02-13) ↗

Cite this data

StockData. (2026). Amgen EPOGEN (epoetin alfa ($M), annual FY2016–FY2019 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-epogen-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.